Company news
Assembly Biosciences, Inc. (NASDAQ:ASMB) news
Assembly Biosciences, Inc. news releases on 6ix. Latest, Nov 10, 2023: Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Press releases — page 2
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 9, 2023
Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®
November 9, 2023
Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates
November 7, 2023
Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
November 7, 2023
Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
October 16, 2023
Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
October 10, 2023
Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
October 1, 2023
Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
September 18, 2023
Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates
August 8, 2023
Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop
July 16, 2023
Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023
June 20, 2023
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023
June 6, 2023
Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference
May 22, 2023
Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights
May 3, 2023
Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update
April 17, 2023
Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights
March 21, 2023
Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes
February 14, 2023
Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334
December 18, 2022
Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334
November 13, 2022
Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation
November 7, 2022
Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV
November 3, 2022
Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®
October 23, 2022
Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A. Okazaki as Successor
October 4, 2022
Assembly Biosciences to Host Webcast on August 31, 2022, Introducing Two New Research Programs Targeting Recurrent HSV-2 Infection and Transplant-Associated Herpesvirus Diseases
August 23, 2022
Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
August 8, 2022
Assembly Biosciences Announces Program Reprioritization and Organizational Update
July 19, 2022
Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL’s International Liver Congress™ 2022
June 21, 2022
Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022
June 20, 2022
Assembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL’s International Liver Congress™ 2022
June 7, 2022
Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection
June 5, 2022
Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
May 11, 2022
Assembly Biosciences to Highlight New Research Program for HBV/HDV Entry Inhibition in Webcast on March 31, 2022
March 20, 2022
Assembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights
March 9, 2022
Assembly Biosciences to Present During the SVB Leerink 11th Annual Global Healthcare Conference
February 8, 2022
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 6, 2022
Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference
January 5, 2022
Assembly Biosciences Outlines Anticipated 2022 Pipeline Development Milestones
January 3, 2022
Assembly Biosciences Presents New Data at AASLD The Liver Meeting™ Highlighting the Progress of its HBV Core Inhibitor Portfolio
November 11, 2021
Assembly Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights
November 3, 2021
Assembly Biosciences Abstracts Selected for Presentation at the Upcoming AASLD The Liver Meeting®
October 31, 2021
Antios Therapeutics and Assembly Biosciences Announce Clinical Collaboration Agreement to Evaluate the Combination of ATI-2173 and Vebicorvir in Patients with Chronic Hepatitis B Virus Infection
October 18, 2021
Assembly Bio Announces October Conference Participation
October 5, 2021
Assembly Bio Announces Decision to Discontinue Clinical Development of ABI-H2158
August 31, 2021
Assembly Bio Selects Fourth HBV Core Inhibitor Candidate for Advancement Into Clinical Development
August 17, 2021
Assembly Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights
August 4, 2021
Assembly Bio Announces Key Promotions to Leadership Team
August 2, 2021
Nobel Laureate Dr. Michael Houghton Appointed to Assembly Biosciences Board of Directors
July 19, 2021
Assembly Biosciences Presents Data from HBV Core Inhibitor Programs at the International Liver Congress™ EASL 2021
June 22, 2021
Assembly Biosciences to Present Data from HBV Core Inhibitor Programs at The International Liver Congress™ EASL 2021
June 8, 2021
Dr. Lisa Johnson-Pratt Joins Assembly Biosciences Board of Directors
May 23, 2021